JP2024509910A - Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 - Google Patents

Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 Download PDF

Info

Publication number
JP2024509910A
JP2024509910A JP2023555203A JP2023555203A JP2024509910A JP 2024509910 A JP2024509910 A JP 2024509910A JP 2023555203 A JP2023555203 A JP 2023555203A JP 2023555203 A JP2023555203 A JP 2023555203A JP 2024509910 A JP2024509910 A JP 2024509910A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
domain
binding protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023555203A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509910A5 (https=
Inventor
マリア ソビエライ，アンナ
ベルト シャイフェレ，ファビアン
ユングミヒェル，シュテファニー
ボッラス，レオナルド
ヴァルデマー ヴィンゲ ライスナー，クリスティアン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cdr-Life AG
Original Assignee
Cdr-Life AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cdr-Life AG filed Critical Cdr-Life AG
Publication of JP2024509910A publication Critical patent/JP2024509910A/ja
Publication of JP2024509910A5 publication Critical patent/JP2024509910A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2023555203A 2021-03-09 2022-03-09 Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質 Pending JP2024509910A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163158691P 2021-03-09 2021-03-09
US63/158,691 2021-03-09
US202163172864P 2021-04-09 2021-04-09
US63/172,864 2021-04-09
PCT/IB2022/052119 WO2022190009A1 (en) 2021-03-09 2022-03-09 Mage-a4 peptide-mhc antigen binding proteins

Publications (2)

Publication Number Publication Date
JP2024509910A true JP2024509910A (ja) 2024-03-05
JP2024509910A5 JP2024509910A5 (https=) 2025-03-17

Family

ID=80787264

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023555203A Pending JP2024509910A (ja) 2021-03-09 2022-03-09 Ｍａｇｅ－ａ４ペプチド－ｍｈｃ抗原結合タンパク質

Country Status (8)

Country Link
US (2) US11912771B2 (https=)
EP (1) EP4304726A1 (https=)
JP (1) JP2024509910A (https=)
KR (1) KR20230169944A (https=)
AU (1) AU2022233285A1 (https=)
CA (1) CA3210289A1 (https=)
MX (1) MX2023010541A (https=)
WO (1) WO2022190009A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2024007473A (es) 2021-12-14 2024-09-10 Cdr Life Ag Activador del linfocito t dirigido al mhc doble.
CA3264474A1 (en) 2022-09-14 2024-03-21 Cdr-Life Ag MAGE-A4 DOUBLE T LYMPHOCYTE ENGAGEMENT
CN119490592B (zh) * 2023-08-14 2025-11-18 东莞市朋志生物科技有限公司 一种抗κ型轻链抗体及其应用
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018225732A1 (ja) * 2017-06-05 2018-12-13 国立大学法人三重大学 Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
JP2019513383A (ja) * 2016-04-08 2019-05-30 アダプティミューン・リミテッド Ｔ細胞受容体
WO2020193767A1 (en) * 2019-03-27 2020-10-01 Medigene Immunotherapies Gmbh Mage a4 t cell receptors
WO2021016585A1 (en) * 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2022535479A (ja) * 2019-12-18 2022-08-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199231B1 (en) 1991-05-23 2007-04-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-4 and 41 and uses thereof
GB9524973D0 (en) 1995-12-06 1996-02-07 Lynxvale Ltd Viral vectors
WO2000020445A2 (en) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Tumor antigens and ctl clones isolated by a novel procedure
US7311914B2 (en) 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
WO2004016740A2 (en) 2002-08-15 2004-02-26 Epitomics, Inc. Humanized rabbit antibodies
AU2003259718A1 (en) 2003-08-07 2005-03-07 Epitomics, Inc. Methods for humanizing rabbit monoclonal antibodies
US7807392B1 (en) 2003-09-15 2010-10-05 Celera Corporation Lung disease targets and uses thereof
JP5276846B2 (ja) 2005-09-13 2013-08-28 国立大学法人三重大学 Ｔ細胞レセプターをコードする核酸が挿入されてなるベクター及び該レセプターを発現する細胞
RU2009137582A (ru) 2007-03-12 2011-04-20 Эсбатек Аг (Ch) Инженерия и оптимизация одноцепочечных антител на основе последовательности
KR20170036814A (ko) 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
EP2164961B1 (en) 2007-06-25 2015-01-07 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CA2728829C (en) 2008-06-25 2018-01-02 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
PL2307458T3 (pl) 2008-06-25 2018-08-31 Esbatech, An Alcon Biomedical Research Unit Llc Humanizacja przeciwciał króliczych z zastosowaniem uniwersalnego zrębu przeciwciała
BR112012004546A8 (pt) * 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
SMT202200306T1 (it) 2016-04-08 2022-09-14 Immunocore Ltd Recettori di cellule t
BR112018070637A2 (pt) 2016-04-08 2019-02-05 Adaptimmune Ltd receptores de células t
WO2017201493A1 (en) 2016-05-20 2017-11-23 Harpoon Therapeutics, Inc. Single chain variable fragment cd3 binding proteins
EP3509635A1 (en) * 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
US10859566B2 (en) 2017-03-20 2020-12-08 Genocea Biosciences, Inc. Treatment methods
US20210147550A1 (en) 2017-08-18 2021-05-20 Joshua Michael Francis Antigen-binding proteins targeting shared antigens
EP3731876A4 (en) 2017-12-28 2022-04-06 Gritstone bio, Inc. ANTIGEN-BINDING PROTEINS TARGETING SHARED ANTIGENS
GB201803750D0 (en) 2018-03-08 2018-04-25 Immunocore Ltd Method
JP7326764B2 (ja) 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
CA3102254A1 (en) 2018-06-04 2019-12-12 Apo-T B.V. Methods and means for attracting immune effector cells to tumor cells
CN108866098A (zh) 2018-07-27 2018-11-23 北京安斯晨睿生物科技有限公司 携带mage-a4突变抗原基因的重组腺相关病毒载体及其构建方法与应用
GB201819540D0 (en) 2018-11-30 2019-01-16 Adaptimmune Ltd T cell modification
GB201901306D0 (en) 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
PH12021553152A1 (en) 2019-06-18 2022-08-15 Regeneron Pharma Mage-a4 t cell receptors and methods of use thereof
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
CN110333352A (zh) 2019-08-07 2019-10-15 基因科技（上海）股份有限公司 肿瘤相关自身抗体及肿瘤标志物联合检测试剂盒
EP4139347A4 (en) 2020-04-24 2024-06-05 Memorial Sloan Kettering Cancer Center Anti-cd3 antibodies and uses thereof
CN116096754A (zh) 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法
EP4149631A1 (en) 2020-05-13 2023-03-22 Adaptimmune Limited Method of treatment of cancer or tumour
US20230190803A1 (en) 2020-05-13 2023-06-22 Adaptimmune Limited Method of treatment of cancer or tumour
CN114524878B (zh) 2020-11-23 2024-08-02 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
US12435444B2 (en) 2021-03-09 2025-10-07 Cdr-Life Ag Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
MX2023010541A (es) 2021-03-09 2023-11-24 Cdr Life Ag Proteinas de union al antigeno del peptido del mhc mage-a4.
AU2022271212A1 (en) 2021-05-04 2023-11-30 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
WO2022262678A1 (zh) 2021-06-15 2022-12-22 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
US20240327543A1 (en) 2021-08-02 2024-10-03 Shenghe (China) Biopharmaceutical Co., Ltd. Multispecific antigen-binding protein and use thereof
CN117730103A (zh) 2021-08-02 2024-03-19 盛禾(中国)生物制药有限公司 一种多特异性抗原结合蛋白及其应用
EP4380631A4 (en) 2021-08-04 2025-06-25 Abpro Corporation Cd3 targeting antibodies and uses thereof
EP4377360A4 (en) 2021-09-17 2025-10-15 Adimab Llc Anti-cd3 antibodies

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019513383A (ja) * 2016-04-08 2019-05-30 アダプティミューン・リミテッド Ｔ細胞受容体
WO2018225732A1 (ja) * 2017-06-05 2018-12-13 国立大学法人三重大学 Ｍａｇｅ－ａ４由来ペプチドを認識する抗原結合性タンパク質
WO2020193767A1 (en) * 2019-03-27 2020-10-01 Medigene Immunotherapies Gmbh Mage a4 t cell receptors
WO2021016585A1 (en) * 2019-07-24 2021-01-28 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2022535479A (ja) * 2019-12-18 2022-08-09 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｈｌａ－ａ２／ｍａｇｅ－ａ４に結合する抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AKAHORI Y.: "J-1036. Development of TCR-like scFv CAR that recognizes MAGE-A4230-239/HLA-A*02:01 complex.", CANCER SCIENCE, vol. 109, Suppl 1, JPN7026001056, September 2018 (2018-09-01), pages 102, ISSN: 0005818102 *
SANDERSON JP. ET AL.: "Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell", ONCOIMMUNOLOGY, vol. 9, 1, JPN7026001057, 24 November 2019 (2019-11-24), pages 1682381, ISSN: 0005818103 *

Also Published As

Publication number Publication date
EP4304726A1 (en) 2024-01-17
KR20230169944A (ko) 2023-12-18
CA3210289A1 (en) 2022-09-15
US20220380472A1 (en) 2022-12-01
WO2022190009A1 (en) 2022-09-15
AU2022233285A1 (en) 2023-10-19
MX2023010541A (es) 2023-11-24
US11912771B2 (en) 2024-02-27
US20240279344A1 (en) 2024-08-22

Similar Documents

Publication Publication Date Title
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
US12435444B2 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
US12509520B2 (en) Anti-CD3 and anti-CD123 bispecific antibody and use thereof
US20250144141A1 (en) Mage-a4 peptide dual t cell engagers
WO2022117032A1 (zh) 抗cd22的纳米抗体及其用途
TW202340240A (zh) 多特異性抗體及其藥物用途
US20250002586A1 (en) Dual mhc-targeting t cell engager
WO2023186100A1 (zh) 抗ror1的抗体及其用途
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
CN116234559A (zh) 抗cd22单结构域抗体和治疗性构建体
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白
WO2025210181A1 (en) Antigen binding proteins targeting an hla-restricted kk-lc-1 peptide
WO2026013159A1 (en) Antibodies binding to constant domains of gamma delta t-cell receptors
KR20250143344A (ko) 항-cdh6 항체 및 이의 용도
WO2025146128A1 (zh) 抗liv-1的抗体及其用途

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240502

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250307

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260306

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260317